Bibliography
- Winum JY, Scozzafava A, Montero JL, Supuran CT. Therapeutic potential of sulfamides as enzyme inhibitors. Med Res Rev 2006;26:767-92
- Winum JY, Scozzafava A, Montero JL, Supuran CT. The sulfamide motif in the design of enzyme inhibitors. Expert Opin Ther Patents 2006;16:27-47
- Crystalgenomics, Inc. Sulfamide derivatives and pharmaceutical compositions for upregulation of lipid metabolism comprising same. WO2006006832; 2006
- Actelion Pharmaceutical, Ltd. Novel sulfamides. WO2006051502; 2006
- Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008;327:736-45
- BASF Aktiengelellschaft, method for production of 1-alkyl-3-phenyluracils. WO 2006125746; 2006
- Bristol-Myers Squibb Company. Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors. US 2007270405; 2007
- Bristol-Myers Squibb Company. Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors. US 2007275930; 2007
- Sanofi-Aventis Deutschland GMBH. Piperidinesulfonylureas and –thioureas, their preparation, their use and pharmaceutical compositions comprising them. WO 2006063722; 2006
- AstraZeneca UK Limited. Pyrimidine sulfonamide derivatives as chemokine receptor modulators. WO 2006024823; 2006
- Johnson & Johnson. Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents. US 2006276528-A1; 2006
- Janssen Pharmaceutica, N.V. Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents. WO 2006023861-A1; 2006
- Janssen Pharmaceutica, N.V. Co-therapy for the treatment of epilepsy Zand related disorders. WO 2007137164-A2; 2007
- Janssen Pharmaceutica, N.V. Co-therapy for the treatment of epilepsy and related disorders. WO 2007137167-A2; 2007
- Maryanoff BE, McComsey DF, Costanzo MJ, et al. Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform. J Med Chem 2005;48:1941-47
- Wyeth. Substituted benzothiadiainedioxide derivatives and methods of their use. WO 200873958-A2; 2008
- Sanofi-Aventis Deutschland GMBH. Substituted benzoylguandines method for production and use thereof as medicament or diagnostic and medicament comprising the same. WO 2006050830-A1; 2006
- Bristol-Myers Squibb Company. Indole inhibitors of 15-lipogenase. US 20060063822-A1; 2006